$COCP
Cocrystal Pharma, Inc. Stock $cocp

$cocp Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011613 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.208M	$1.399M	$5.990M
YoY Change	0.33%	15.14%	4.26%
% of Gross Profit
Research & Development	$2.950M	$4.267M	$15.17M
YoY Change	-24.49%	29.81%	22.41%
% of Gross Profit
Depreciation & Amortization	$35.00K	$39.00K	$189.0K
YoY Change	-22.22%	-18.75%	2.16%
% of Gross Profit
Operating Expenses	$4.158M	$5.666M	$21.16M
YoY Change	-18.65%	25.86%	-45.51%
Operating Profit	-$4.158M		-$18.56M
YoY Change	-18.65%		-52.2%
Interest Expense	-$220.0K	$202.0K	$575.0K
YoY Change		20100.0%	28650.0%
% of Operating Profit
Other Income/Expense, Net	$202.0K		$575.0K
YoY Change	-358.97%		-7287.5%
Pretax Income	-$3.956M	-$4.464M	-$17.98M
YoY Change	-23.76%	-0.82%	-53.69%
Income Tax
% Of Pretax Income
Net Earnings	-$3.956M	-$4.464M	-$17.98M
YoY Change	-23.76%	-0.82%	-53.69%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.39		-$1.87
Diluted Earnings Per Share	-$0.39	-$0.44	-$1.86
COMMON SHARES
Basic Shares Outstanding	10.17M shares	10.17M shares	9.651M shares
Diluted Shares Outstanding	10.17M shares		9.651M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.84M	$26.35M	$26.35M
YoY Change	-35.72%	-29.05%	-29.05%
Cash & Equivalents	$21.84M	$26.35M	$26.35M
Short-Term Investments
Other Short-Term Assets	$1.647M	$1.848M	$1.848M
YoY Change	-28.36%	-20.28%	-20.28%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$24.49M	$29.09M	$29.09M
YoY Change	-34.22%	-27.59%	-27.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$244.0K	$2.122M	$2.122M
YoY Change	-27.81%	520.47%	244.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$46.00K	$46.00K	$46.00K
YoY Change	0.0%	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$2.054M	$2.168M	$2.168M
YoY Change	239.5%	227.49%	227.49%
TOTAL ASSETS
Total Short-Term Assets	$24.49M	$29.09M	$29.09M
Total Long-Term Assets	$2.054M	$2.168M	$2.168M
Total Assets	$26.55M	$31.26M	$31.26M
YoY Change	-29.85%	-23.46%	-23.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.234M	$1.222M	$1.222M
YoY Change	-53.5%	99.02%	99.02%
Accrued Expenses	$1.145M	$2.040M	$2.040M
YoY Change	133.2%	242.86%	242.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$2.379M	$3.262M	$3.262M
YoY Change	-24.36%	168.26%	168.26%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.582M	$1.613M	$1.613M
YoY Change	5759.26%	2729.82%	2729.82%
Total Long-Term Liabilities	$1.582M	$1.613M	$1.613M
YoY Change	5759.26%	2729.82%	2729.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.379M	$3.262M	$3.262M
Total Long-Term Liabilities	$1.582M	$1.613M	$1.613M
Total Liabilities	$3.961M	$4.875M	$4.875M
YoY Change	24.87%	282.95%	282.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$319.9M	-$315.9M
YoY Change	5.53%	6.04%
Common Stock	$342.5M	$342.3M
YoY Change	1.38%	1.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$22.59M	$26.38M	$26.38M
YoY Change
Total Liabilities & Shareholders Equity	$26.55M	$31.26M	$31.26M
YoY Change	-29.85%	-23.46%	-23.46%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$3.956M	-$4.464M	-$17.98M
YoY Change	-23.76%	-0.82%	-53.69%
Depreciation, Depletion And Amortization	$35.00K	$39.00K	$189.0K
YoY Change	-22.22%	-18.75%	2.16%
Cash From Operating Activities	-$4.503M	-$3.326M	-$14.67M
YoY Change	44.74%	-32.03%	-31.58%
INVESTING ACTIVITIES
Capital Expenditures	$8.000K	$58.00K	$118.0K
YoY Change	-82.22%	383.33%	59.46%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$8.000K	-$58.00K	-$118.0K
YoY Change	-82.22%	383.33%	59.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$4.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		3.000K	3.993M
YoY Change		-142.86%	-14888.89%
NET CHANGE
Cash From Operating Activities	-$4.503M	-3.326M	-14.67M
Cash From Investing Activities	-$8.000K	-58.00K	-118.0K
Cash From Financing Activities		3.000K	3.993M
Net Change In Cash	-$4.511M	-3.381M	-10.79M
YoY Change	42.62%	-31.17%	-49.89%
FREE CASH FLOW
Cash From Operating Activities	-$4.503M	-$3.326M	-$14.67M
Capital Expenditures	$8.000K	$58.00K	$118.0K
Free Cash Flow	-$4.511M	-$3.384M	-$14.78M
YoY Change	42.93%	-31.01%	-31.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q4	us-gaap	Goodwill Goodwill		usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38418
CY2023	dei	Entity Registrant Name EntityRegistrantName	Cocrystal Pharma, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	35-2528215
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	19805 North Creek Parkway
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Bothell
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	98011
CY2023	dei	City Area Code CityAreaCode	(877)
CY2023	dei	Local Phone Number LocalPhoneNumber	262-7123
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value
CY2023	dei	Trading Symbol TradingSymbol	COCP
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	18500000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10173790	shares
CY2023	dei	Auditor Firm AuditorFirmId	572
CY2023	dei	Auditor Name AuditorName	Weinberg & Company
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26353000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37144000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	75000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	75000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	890000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	716000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1773000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2243000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	29091000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	40178000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	271000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	342000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	46000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	46000	usd
CY2023Q4	COCP	Operating Lease Right Of Use Assets Due To Related Party OperatingLeaseRightOfUseAssetsDueToRelatedParty	42000	usd
CY2022Q4	COCP	Operating Lease Right Of Use Assets Due To Related Party OperatingLeaseRightOfUseAssetsDueToRelatedParty	99000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1851000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	274000	usd
CY2023Q4	us-gaap	Assets Assets	31259000	usd
CY2022Q4	us-gaap	Assets Assets	40840000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3022000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	976000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7000	usd
CY2023Q4	COCP	Related Party Operating Lease Liabilities Current RelatedPartyOperatingLeaseLiabilitiesCurrent	42000	usd
CY2022Q4	COCP	Related Party Operating Lease Liabilities Current RelatedPartyOperatingLeaseLiabilitiesCurrent	59000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	240000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	233000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3262000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1216000	usd
CY2023Q4	COCP	Operating Lease Liabilities Related Party Noncurrent OperatingLeaseLiabilitiesRelatedPartyNoncurrent	0	usd
CY2022Q4	COCP	Operating Lease Liabilities Related Party Noncurrent OperatingLeaseLiabilitiesRelatedPartyNoncurrent	42000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1613000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1613000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	57000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4875000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1273000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10174000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10174000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8143000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8143000	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	10000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	342288000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	337489000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-315914000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-297930000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	26384000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	39567000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31259000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40840000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15169000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12392000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5990000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5745000	usd
CY2023	COCP	Legal Settlement LegalSettlement	-2600000	usd
CY2022	COCP	Legal Settlement LegalSettlement	1600000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	19092000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	18559000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	38829000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-18559000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-38829000	usd
CY2023	us-gaap	Interest Expense InterestExpense	-640000	usd
CY2022	us-gaap	Interest Expense InterestExpense	2000	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	12000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21536000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37219000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	58755000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26428000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37219000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-65000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-18000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9651000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9651000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	77549000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	855000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38837000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	39567000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	39567000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	801000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	26384000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-17984000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-38837000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	189000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	185000	usd
CY2023	COCP	Right Of Use Assets Related To Lease Expenses RightOfUseAssetsRelatedToLeaseExpenses	-1577000	usd
CY2022	COCP	Right Of Use Assets Related To Lease Expenses RightOfUseAssetsRelatedToLeaseExpenses	203000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	19092000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	801000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	855000	usd
CY2023	COCP	Change In Operating Lease Liabilities ChangeInOperatingLeaseLiabilities	-1563000	usd
CY2022	COCP	Change In Operating Lease Liabilities ChangeInOperatingLeaseLiabilities	209000	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	12000	usd
CY2023	COCP	Increase Decrease In Value Added Tax Receivable IncreaseDecreaseInValueAddedTaxReceivable	-174000	usd
CY2022	COCP	Increase Decrease In Value Added Tax Receivable IncreaseDecreaseInValueAddedTaxReceivable	-716000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-470000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1675000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2046000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-321000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14666000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21435000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	118000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	74000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-118000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-74000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	7000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3993000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-27000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10791000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-17984000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14666000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26353000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_z6rFMOQfwv99" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zwOb1CwzgCuk">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of the Company’s consolidated financial statements in conformance with U.S. GAAP requires the Company’s management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The significant estimates in the Company’s consolidated financial statements relate to the valuation of equity awards and derivative liabilities, recoverability of deferred tax assets, estimated useful lives of fixed assets, and forecast assumptions used in the impairment testing of goodwill. The Company bases estimates and assumptions on historical experience, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis, and its actual results may differ from estimates made under different assumptions or conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zPtzAlks6ci6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zTNJ0uumUlBh">Concentrations of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash deposited in accounts held at two U.S. financial institutions, which may, at times, exceed federally insured limits of $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20231231__us-gaap--FinancialInstrumentAxis__custom--UnitedStatesFinancialInstitutionsTwoMember_zZQ8ysGPf539" title="Cash FDIC insured amount">250,000</span> for each institution accounts are held. At December 31, 2023 and 2022, our primary operating account held approximately $<span id="xdx_90C_eus-gaap--Cash_iI_pp0p0_c20231231_zBJJ1lOdrZu5" title="Cash">16,327,000</span> and $<span id="xdx_903_eus-gaap--Cash_iI_pp0p0_c20221231_zcYuxiS1I5Y3" title="Cash">37,144,000</span>, respectively, and our collateral account balance of $<span id="xdx_90D_eus-gaap--RestrictedCashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20231231_zE6lZUp77Mmb" title="Restricted cash">75,000</span> as of December 31, 2023 and other cash accounts are maintained at different institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risks thereof.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Cash	16327000	usd
CY2022Q4	us-gaap	Cash Cash	37144000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	75000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26353000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37144000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	75000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	75000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	890000	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	823000	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	569000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	363000	shares
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-65000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-18000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26428000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37219000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	130000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1691000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	232000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2074000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1803000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	271000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	189000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	185000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	19092000	usd
CY2022Q2	us-gaap	Amortization Of Above And Below Market Leases AmortizationOfAboveAndBelowMarketLeases	19092000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1222000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	614000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	109000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3022000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	976000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10174000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10174000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8143000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8143000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	2.67
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0396	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1202	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M7D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	12.01
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0289	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1196	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M29D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	801000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	855000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	717000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	558000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0.0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.38
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y2M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	279000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0.0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	17.17
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y2M12D
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.72
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	558000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	350000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	275000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	484000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	11000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	20000	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	844000	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	854000	shares
CY2022Q3	COCP	Resevation Fee ResevationFee	1700000	usd
CY2022Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	6800000	usd
	COCP	Resevation Fee ResevationFee	1700000	usd
	COCP	Additional Milestone Payments AdditionalMilestonePayments	5100000	usd
CY2023	COCP	Resevation Fee ResevationFee	440000	usd
CY2023Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1280000	usd
CY2023	COCP	Additional Milestone Payments AdditionalMilestonePayments	2610000	usd
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3050000.00	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	1900000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22005000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21368000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	583000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	474000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3196000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2710000	usd
CY2023Q4	COCP	Deferred Tax Assets Capitalized And Research Expenditures DeferredTaxAssetsCapitalizedAndResearchExpenditures	5288000	usd
CY2022Q4	COCP	Deferred Tax Assets Capitalized And Research Expenditures DeferredTaxAssetsCapitalizedAndResearchExpenditures	2595000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	848000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	487000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31920000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27633000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	29000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	27000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	410000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	60000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	439000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	87000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	31481000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	27546000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31481000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27546000	usd
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	Under the CARES Act, the Internal Revenue Code was amended to allow for federal NOL carrybacks for five years to offset previous income, or can be carried forward indefinitely to offset 100% of the taxable income for the tax year 2020 and 80% of the taxable income for the tax years 2021 and thereafter.
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	The federal NOL carryforwards begin to expire in 2026.
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.103	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.028	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.007	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.219	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.102	pure
CY2023	COCP	Effective Income Tax Rate Reconciliation Equity EffectiveIncomeTaxRateReconciliationEquity	-0.004	pure
CY2022	COCP	Effective Income Tax Rate Reconciliation Equity EffectiveIncomeTaxRateReconciliationEquity	-0.014	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.015	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	233000	usd
CY2023	COCP	Cash Paid For Amounts Included In Measurement Of Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities	233000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.062	pure
CY2023Q4	COCP	Operating Lease Right Of Use Assets Due To Related Party OperatingLeaseRightOfUseAssetsDueToRelatedParty	42000	usd
CY2022Q4	COCP	Operating Lease Right Of Use Assets Due To Related Party OperatingLeaseRightOfUseAssetsDueToRelatedParty	99000	usd
CY2023Q4	COCP	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	950000	usd
CY2022Q4	COCP	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	592000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1851000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	274000	usd
CY2023Q4	COCP	Related Party Operating Lease Liabilities Current RelatedPartyOperatingLeaseLiabilitiesCurrent	42000	usd
CY2022Q4	COCP	Related Party Operating Lease Liabilities Current RelatedPartyOperatingLeaseLiabilitiesCurrent	59000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	240000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	233000	usd
CY2023Q4	COCP	Related Party Operating Lease Liabilities Noncurrent RelatedPartyOperatingLeaseLiabilitiesNoncurrent	0	usd
CY2022Q4	COCP	Related Party Operating Lease Liabilities Noncurrent RelatedPartyOperatingLeaseLiabilitiesNoncurrent	42000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1613000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	57000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1853000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	290000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	264000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	344000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	355000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	365000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	376000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	513000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2217000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	364000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1853000	usd
CY2023Q4	COCP	Finance Lease Right Of Use Assets FinanceLeaseRightOfUseAssets	162000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	162000	usd
CY2022Q4	COCP	Finance Lease Right Of Use Assets FinanceLeaseRightOfUseAssets	194000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	158000	usd
CY2022Q2	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	1359064	usd
CY2023Q1	us-gaap	Loss Contingency Settlement Agreement Court LossContingencySettlementAgreementCourt	1.6
CY2023Q3	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	1600000	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-011613-index-headers.html	Edgar Link	pending
0001493152-24-011613-index.html	Edgar Link	pending
0001493152-24-011613.txt	Edgar Link	pending
0001493152-24-011613-xbrl.zip	Edgar Link	pending
cocp-20231231.xsd	Edgar Link	pending
ex14-1.htm	Edgar Link	pending
ex19-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex31-3.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
cocp-20231231_cal.xml	Edgar Link	unprocessable
cocp-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cocp-20231231_def.xml	Edgar Link	unprocessable
cocp-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$COCP
Cocrystal Pharma, Inc. Stock $cocp

2024 Q1 Form 10-K Financial Statement

#000149315224011613 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COCP Cocrystal Pharma, Inc. Stock $cocp

2024 Q1 Form 10-K Financial Statement

#000149315224011613 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COCP
Cocrystal Pharma, Inc. Stock $cocp